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Background: Psoriasis and psoriatic arthritis (PsA) are in-
cluded in the group of immune-mediated inflammatory dis-
eases (IMIDs) caused by systemic inflammation; however, 
indicators for monitoring inflammatory activity in patients 
with psoriasis, such as the Psoriasis Area and Severity Index 
(PASI), are limited. Objective: To determine whether the 
Psoriatic Arthritis Screening and Evaluation (PASE) ques-
tionnaire can be used to monitor disease activity in patients 
with psoriasis. Methods: This was a multicenter, non-
interventional, cross-sectional study. Demographic factors 
and PASI and PASE scores were collected to investigate asso-
ciations between each. Results: PASE data were available for 
1,255 patients, of whom 498 (39.7%) had a score of ≥37. 
Compared with the group with PASE score ＜37, the group 
with score ≥37 had a higher proportion of women (34.9% 
vs. 48.8%, p＜0.0001), older mean age at diagnosis (36.4 vs. 
41.7 years, p＜0.0001), more severe disease activity using 
PASI and body surface area measures (p=0.0021 and 
p=0.0008, respectively), and higher mean body mass index 
(23.7 vs. 24.1, p=0.0411). In a multiple linear regression 
model, PASE score was positively associated with cutaneous 
disease activity (p＜0.0001). Conclusion: After risk-adjust-
ment, PASE was positively associated with PASI, which sug-
gests that PASE can be sensitive to disease activity. Since 
psoriasis is regarded as one of the IMIDs, PASE may be uti-
lized as a tool not only to screen PsA but also to monitor dis-
ease activity. (Ann Dermatol 31(1) 29∼36, 2019)
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INTRODUCTION
Psoriasis is a chronic inflammatory skin disease with prev-
alence of 1%∼3% worldwide. Skin lesions are charac-
terized by multiple, well-demarcated, raised, red plaques 
with a white scaly surface1. It is considered to be a sys-
temic disease because it is frequently accompanied by co-
morbidities that include psoriatic arthritis (PsA), diabetes, 
dyslipidemia, and cardiovascular disease2,3. PsA is an in-
flammatory arthritis associated with psoriasis and its prev-
alence varies between 0.02% and 0.42% in the general 
population4,5 and between 6% and 48% in psoriasis pa-
tients6. The skin manifestations of psoriasis precede symp-
toms of arthritis by 10 years on average and, in 15% of the 
total cases, PsA and psoriasis either occur simultaneously 
or PsA precedes the skin disease7. 
Early diagnosis of and prompt intervention for PsA are cru-
cial because delaying treatment may result in devastating, 
irreversible joint damage. Moreover, PsA is known to be 
an important determinant of vascular comorbidities in 
psoriatic patients8. Dermatologists, therefore, have an im-
portant role in examining other body systems as well as 
the skin lesions associated with psoriasis that might be in-
volved in this immune-mediated inflammatory disease 
(IMID). 
However, there is no specific indicator for monitoring sys-
temic inflammation in patients with psoriasis, such as the 
C-reactive protein levels used in clinical practice to mon-
itor disease activity in rheumatic and inflammatory bowel 
disease. On the other hand, some screening tools have 
been developed for the identification of PsA in patients 
with psoriasis; these include the Psoriatic Arthritis Screening 
and Evaluation (PASE)9, the Psoriatic and Arthritic 
Questionnaire10, the Psoriasis Epidemiology Screening 
Tool11, the Toronto Psoriatic Arthritis Screen12, and the 
Early Arthritis for Psoriatic Patients13. Of these, PASE has 
the most questions, with possible scores of 0 to 75, with a 
broader range to screen arthritis-related symptoms and 
functions. In this analysis, we sought to determine wheth-
er the symptoms of inflammatory arthritis, and their effect 
on patient functioning, are positively associated with cuta-
neous disease activity in order to enable better manage-
ment of patients with psoriasis, in a holistic approach to 
IMID. 
MATERIALS AND METHODS 
Study design 
The EPI-PSODE14 study was a multicenter, noninterven-
tional, cross-sectional study. The 25 participating centers 
were primarily university hospitals, located across Korea 
(with the exception of the Jeju island region). This study 
was reviewed and approved by the Institutional Review 
Board of each center (Corresponding author's institution 
[Asan Medical Center]: IRB no. 2013-0161). To extract a 
representative sample reflecting the distribution of psor-
iasis in Korea, the numbers and locations of the study cen-
ters were selected on the basis of population distribution 
and health insurance reimbursement data of patients with 
psoriasis. Patients were examined and enrolled consec-
utively in order of visiting the center. After obtaining in-
formed consent, all study procedures were performed on 
1 day. The study patients were adults aged 20 years or 
older diagnosed with psoriasis. Data were collected by in-
terviewing and assessing the patients on demographic fac-
tors (age, gender, height, weight, waist circumference, dis-
ease duration, age at diagnosis, family history in first-de-
gree relative, drinking/smoking history, and medication 
history). Physical examinations for disease-severity meas-
ures (Psoriasis Area and Severity Index [PASI] and body 
surface area [BSA]) and blood pressure were performed. 
Quality of life was evaluated by the Dermatologic Life 
Quality Index (DLQI) and Medical Outcomes Study 
36-Item Short-Form Health Survey (SF-36)15. In order to 
evaluate patient satisfaction with various therapies, ques-
tions from the existing Medication Satisfaction 
Questionnaire (MSQ) were included16. Lastly, the PASE 
tool was used to assess arthritis-related symptoms and 
functions. 
Statistical analysis 
Descriptive statistics for continuous variables are pre-
sented as means with standard deviation (SD), and dichot-
omous variables are presented as frequencies with percen-
tages in parentheses. Respective proportions are presented 
using 37 points17,18, 44 points19, and 47 points9 as cut-off 
values in PASE, and variables collected were compared to 
assess the statistical significance of any differences among 
the groups using a cutoff threshold of 37 points of PASE 
(PASE ＜37 and PASE ≥37) based on a validation study 
for Korean patients (sensitivity of 77.8%, specificity of 
82.3%, positive predictive value of 37.8% and negative 
predictive value of 96.4%)17. We used, where appropriate, 
the Mann-Whitney U-test and t-test for continuous varia-
bles and Pearson’s chi-square test and Fisher’s exact test 
for dichotomous variables, without missing data imputation. 
In addition, multiple linear regression analysis was used to 
assess association between disease activity (using PASI) 
and inflammatory arthritis-related symptoms and functions 
(using PASE) after excluding the effect of each confounder 
such as gender, age, and body mass index (BMI) which 
are considerably related to occurrence of arthritis. All stat-
Usefulness of PASE in Management of Psoriasis
Vol. 31, No. 1, 2019 31
Fig. 1. Proportion of patients by PASE cut-off values. PASE: 
Psoriatic Arthritis Screening and Evaluation.
istical tests were performed using 2-sided tests and p-values 
＜0.05 were considered statistically significant. Analyses 
were performed using the statistical software package SAS 
9.4 (Statistical Analysis System; SAS-Institute, Cary, NC, 
USA).
RESULTS 
Of 1,260 patients who completed the study, PASE data 
were available for 1,255 patients. The proportions of pa-
tients scoring ≥47, ≥44, and ≥37 points were 18.6% 
(n= 233), 24.0% (n=301), and 39.7% (n=498), re-
spectively (Fig. 1). 
At the 37-point cut-off, there were 757 patients in the 
group with PASE ＜37 and 498 in the group with PASE ≥
37. The group with PASE ≥37 had a higher proportion of 
women than the group with PASE ＜37 (48.8% vs. 34.9%, 
p＜0.0001); older mean age (50.5 years vs. 44.7 years, p＜ 
0.0001); and older mean age at diagnosis (41.7 years vs. 
36.4 years, p＜0.0001). The higher-score PASE group 
(PASE ≥37) had more severe disease activity using PASI 
and BSA (difference of PASI=1.5; p=0.0021 and differ-
ence of BSA=3.1; p=0.0008, respectively) than the low-
er-score PASE group (PASE ＜37). Nail involvement and 
family history of psoriasis were more frequent in the PASE 
≥37 group but this did not reach statistical significance. 
The group with PASE ≥37 had higher mean BMI (24.1 vs. 
23.7, p=0.0411) and greater waist circumference (85.87 
cm vs. 83.22 cm, p=0.0002) but there was no significant 
relationship with blood pressure between the 2 groups. A 
significantly lower percentage of patients in the group 
with PASE ≥37 had a smoking and drinking history than 
the group with PASE ＜37, but this appears to be affected 
by the difference in the gender ratio (no statistical sig-
nificance based on Cochran-Mantel-Haenszel [CMH] test 
between the 2 groups stratified by gender; smoking 
(pCMH=0.9297) and drinking (pCMH=0.1261) (data not 
shown). Regarding medication history, only use of sys-
temic treatment was significantly greater in the group with 
PASE ≥37 than the group with PASE ＜37 (66.3% vs. 
58.0%, p=0.0032). DLQI and both physical and mental 
component SF-36 scores were significantly higher in the 
group with PASE ≥37 compared to the group with PASE 
＜37, and satisfaction with treatment was lower in the 
group with PASE ≥37 (p=0.0015) (Table 1). 
A multiple linear regression model was used to explore 
the potential for an association between disease severity 
represented by PASI and PASE scores by designating fac-
tors with representativeness among significant independent 
variables in the univariate analysis. It appeared that female 
gender, age, and BMI affected arthritis symptoms and 
function. PASE and PASI were associated with each other, 
even after adjustment for the these factors (p＜0.0001) 
(Table 2). 
The comparison of scores between the group with PASE 
≥37 and the group with PASE ＜37 for each question of 
the PASE questionnaire is shown in Fig. 2 and Table 3 for 
the symptom subscale and Fig. 3 and Table 4 for the func-
tion subscale. For the symptom subscale, the highest score 
difference between the 2 groups was for question 2, “My 
joints hurt”. The highest score in both groups was for 
question 1, “I feel tired for most of the day”, and the low-
est score in both groups was for question 5, “My joints 
feel hot”. This last question had the lowest score differ-
ence between the groups. For the function subscale, the 
score difference between the 2 groups was highest for 
question 8, “I feel that my joint problems have affected 
my ability to work”, then question 12, “I am unable to be 
as active as I used to be” and question 13, “I feel stiff for 
more than 2 hours after waking up in the morning”. Lastly, 
the question with the lowest score in both groups and the 
lowest score difference between the 2 groups was ques-
tion 10, “I have trouble wearing rings on my fingers or my 
watch”. 
DISCUSSION 
The prevalence of PsA in Korea according to previous 
studies was approximately 9.0%∼14.1%20-22. When PASE 
scores of ≥47, ≥44, and ≥37 were applied as cut-off val-
ues, the proportions of screened patients in each group 
were 18.6%, 24.0%, and 39.7%, respectively. Of these, 
approximately 40% of patients with a cut-off score of ≥37 
validated in the Korean population may require additional 
assessments to confirm a diagnosis of PsA. In our study, 
the prevalence of PsA in patients with psoriasis was nu-
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Table 1. Comparison of related factors between 2 groups divided by PASE 37 
Category n' PASE ＜37 (n=757) PASE ≥37 (n=498) p-value
Demographics
  Gender 1,255
    Male 748 493 (65.1) 255 (51.2) ＜0.0001
    Female 507 264 (34.9) 243 (48.8)
  Age (yr) 1,255 44.7±13.92 50.5±14.66 ＜0.0001
  Age at diagnosis (yr) 1,252 36.4±15.72 41.7±17.11 ＜0.0001
  Disease duration (mo) 1,252 106.6±121.13 113.7±123.58 0.3574
  PASI 1,255 6.87±6.409 8.38±7.905 0.0021
  BSA 1,253 11.9±13.21 15.0±16.36 0.0008
  Nail involvement 1,255 90 (11.9) 65 (13.1) 0.5401
  Family history 1,255 91 (12.0) 68 (13.7) 0.3947
  BMI (kg/m2) 1,254 23.70±3.308 24.12±3.746 0.0411
  Waist circumference (cm) 1,108 83.22±10.218 85.87±12.304 0.0002
  SBP≥140 mmHg or DBP≥90 mmHg 1,160 134 (19.3) 97 (20.9) 0.4900
  Smoking history 1,255 391 (51.7) 216 (43.4) 0.0041
  Drinking history 1,255 512 (67.6) 291 (58.4) 0.0009
Medication history 
  Topical 1,255 712 (94.1) 463 (93.0) 0.4420
  Phototherapy 1,255 394 (61.7) 245 (49.2) 0.3230
  Systemics 1,255 439 (58.0) 330 (66.3) 0.0032
  Biologics 1,255 38 (5.0) 34 (6.8) 0.1779
Patient-reported outcome 
  PASE total score 1,255 24.8±6.81 47.2±7.95 ＜0.0001
  PASE symptom score 1,255 12.2±3.64 22.0±4.08 ＜0.0001
  PASE function score 1,255 12.6±4.17 25.2±5.01 ＜0.0001
  DLQI 1,251 10.3±6.80 14.6±7.12 ＜0.0001
  SF-36 (physical) 1,253 52.1±6.07 43.8±7.86 ＜0.0001
  SF-36 (mental) 1,253 46.0±10.29 37.4±10.61 ＜0.0001
  Satisfaction in MSQ 1,250 461 (61.2) 271 (54.5) 0.0015
Values are presented as number (%) or mean±standard deviation. Percentages were based on the total number of subjects with each
available result in each group. n': Total number of subjects with each available result, PASE: Psoriatic Arthritis Screening and Evaluation,
PASI: Psoriasis Area and Severity Index, BSA: body surface area, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic
blood pressure, DLQI: Dermatology Life Quality Index, SF-36: Medical Outcomes Study 36-Item Short-Form Health Survey, MSQ: 
Medication Satisfaction Questionnaire.






Female gender 3.920 ＜0.0001
Age 0.161 ＜0.0001
BMI 0.136 0.2014
PASE: Psoriatic Arthritis Screening and Evaluation, PASI: Psoriasis
Area and Severity Index, β: regression coefficient, BMI: body 
mass index. 
merically estimated to be 15.0% by applying positive pre-
dictive value of 37.8% to the patients screened with a 
cut-off of 37 points17. In addition, a recent study per-
formed in Japan showed that the prevalence of PsA in pa-
tients with psoriasis reached around 20% in some areas23. 
Continued studies are required to further characterize the 
prevalence of PsA in Korea. 
The maximum score for the PASE is 75; for a continuous 
variable with such a wide range, the ability to detect 
changes becomes relatively greater and sensitivity is high-
er than a continuous variable with a narrow range. In gen-
eral, most patients who develop PsA progress from psor-
iasis alone to psoriasis with PsA and these patients have 
more severe psoriasis24; this finding aligns with our analy-
sis in which the group with PASE ≥37 showed higher 
PASI scores and BSA affected than the group with PASE 
＜37. Moreover, disease severity in psoriasis is associated 
with elevated proinflammatory cytokines25 and this level 
of inflammation is related to the development of hyper-
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Table 4. Comparisons in function subscale of PASE 
PASE Questionnaire PASE ＜37 (n=757) PASE ≥37 (n=498) Difference
8. I feel that my joint problems have affected my ability to work 1.6±0.82 3.4±1.01 −1.9±0.90
9. My joint problems have affected my ability to care for myself, 
e.g. getting dressed or brushing my teeth
1.4±0.70 2.9±1.08 −1.5±0.87
10. I have had trouble wearing rings on my fingers or my watch 1.3±0.63 2.5±1.11 −1.2±0.86
11. I have had trouble getting into or out of a car 1.3±0.59 2.9±1.11 −1.5±0.84
12. I am unable to be as active as I used to be 1.9±1.02 3.7±0.97 −1.8±1.00
13. I feel stiff for more than 2 hours after waking up in the morning 1.6±0.80 3.3±1.00 −1.7±0.88
14. The morning is the worst time of day for me 1.8±0.95 3.3±1.01 −1.5±0.97
15. It takes me a few minutes to get moving to the best of my ability, 
any time of the day
1.8±0.92 3.3±0.94 −1.5±0.93
Values are presented as mean±standard deviation. Difference=PASE≥37–PASE ＜37. PASE: Psoriatic Arthritis Screening and Evaluation.
Table 3. Comparisons in symptom subscale of PASE 
PASE Questionnaire PASE ＜37 (n=757) PASE ≥37 (n=498) Difference
1. I feel tired for most of the day 2.5±1.10 3.7±0.87 −1.2±1.01
2. My joints hurt 1.9±0.99 3.6±0.92 −1.7±0.96
3. My back hurts 2.1±1.11 3.6±0.92 −1.5±1.04
4. My joints become swollen 1.4±0.63 2.8±1.07 −1.4±0.83
5. My joints feel "hot" 1.4±0.61 2.6±1.04 −1.2±0.81
6. Occasionally, an entire finger or toe becomes swollen, making 
it look like a "sausage"
1.4±0.68 2.7±1.12 −1.3±0.88
7. I have noticed that the pain in my joints moves from one joint 
to another, e.g. my wrist will hurt for a few days then my knee 
will hurt and so on
1.4±0.66 2.9±1.09 −1.4±0.85
Values are presented as mean±standard deviation. Difference=PASE≥37–PASE ＜37. PASE: Psoriatic Arthritis Screening and Evaluation.
Fig. 3. Comparisons in function subscale of PASE. PASE: Psoriatic 
Arthritis Screening and Evaluation.
Fig. 2. Comparisons in symptom subscale of PASE. PASE: Psoriatic
Arthritis Screening and Evaluation.
tension26. A systematic review found that there is a greater 
prevalence of hypertension in patients with psoriasis, and 
patients with severe psoriasis are more likely to have hy-
pertension than those with mild psoriasis27, consistent 
with hypertension considered as a type of inflammatory 
disease28. 
The disease severity of psoriasis has been shown to be re-
lated to the activity of inflammation. In our analysis, PASE 
scores were positively associated with PASI scores after 
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adjusting for confounding factors such as female gender, 
age, and BMI which affect arthritis symptoms and our re-
sult also showed positive linearity through each regression 
coefficient (β) in Table 2. In addition, Husni et al.29 con-
firmed that the PASE tool is sensitive to changes in re-
sponse of patients treated with biological therapy, which 
might be applied similarly to change in disease activity or 
systemic inflammation. Therefore, the use of PASE could 
monitor changes in inflammatory activity, in other words 
disease activity, in patients with psoriasis. PASE is not only 
used for PsA screening but also for management of psor-
iasis as an IMID. Patients with PsA showed more severe 
psoriasis than patients without PsA in some studies24,30,31. 
In line with these results, our analysis showed that the 
group with PASE ≥37 had significantly higher PASI and 
BSA affected than the group with PASE ＜37; greater and 
more active systemic inflammation may affect many body 
systems so this increased disease activity may promote the 
development of PsA. The most common identified risk fac-
tor for development of PsA was the presence of nail dis-
ease in many studies30,32,33. In our study, nail involvement 
was higher in the group with PASE ≥37 than the group 
with PASE ＜37, but this was not statistically significant. 
Obesity has also been shown to increase the risk of occur-
rence of PsA in some studies34,35; this suggests that weight 
loss may alleviate disease severity and reduce the risk of 
developing PsA. Consistent with this, the BMI of the group 
with PASE ≥37 was significantly higher in our study than 
that of the group with PASE ＜37. However, further stud-
ies are needed to determine the relationship between obe-
sity and development of PsA in Korean patients with psor-
iasis because the difference in BMI between groups was 
small (0.42 kg/m2) and weight gain may increase the risk 
of osteoarthritis, which is not related to systemic in-
flammation36. 
The association between smoking/drinking and PsA is 
controversial because there have been opposing results 
from a variety of studies37. In our analysis, the percentage 
of patients with a history of smoking was higher in the 
group with PASE ＜37 using a univariate model, though 
there was no statistically significant difference between 
the 2 groups when stratified by gender. In other words, no 
association between smoking and PASE score was identi-
fied in our analysis. Drinking was also not associated with 
PsA when stratified by gender. Tey et al.38 reported that 
sex, age of onset of psoriasis, and a family history of psor-
iasis were not associated with PsA, but our study showed 
that age at diagnosis was significantly higher in the group 
with PASE ≥37 than the group with PASE ＜37. 
A potential limitation of the PASE questionnaire is its 
length, and it may be difficult for patients to complete all 
15 questions in the real-world setting of dermatology clin-
ic practice. However, it may be sufficient to use only the 
questions that showed the greatest difference between the 
two groups. Question 2, “My joints hurt” in the symptom 
subscale and question 8, “I feel that my joint problems 
have affected my ability to work” showed the greatest dif-
ference between the 2 groups in our analysis. According 
to the Turkish PASE tool validation study39, questions 2, 8, 
and 12 indicated the highest sensitivity (77%) for the an-
swers “agree” or “strongly agree”. This result is closely 
aligned with our analysis. If the scores for these questions 
are increased, physicians may consider completing the en-
tire PASE questionnaire with the patient or performing reg-
ular follow-up, at least once every 6 or 12 months so that 
changes in inflammatory activity, which might not be ap-
parent by examination of the skin, may be checked by 
evaluation of joint symptoms. Lastly, further studies are 
needed to support results from the present study. For ex-
ample, a study on specific population excluding con-
founders could be conducted or a study to follow up 
changes in intra-subject setting. 
In conclusion, PASE scores is independently associated 
with PASI scores after risk adjustment and can be sensitive 
to disease activity. From the perspective that psoriasis is 
treated as one of the IMIDs, PASE may be utilized as a 
tool to monitor changes in inflammatory activity and their 
effect on the course of the disease. 
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